Cholesterol and cognition: Rationale for the AD Cholesterol-Lowering Treatment Trial and sex-related differences in β-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits

Annals of the New York Academy of Sciences

Volumn 977, Issue , 2002, Pages 356-366

  Sparks, D Larry ^a   Martins, Ralph ^b   Martin, Tim ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b HOLLYWOOD PRIVATE HOSPITAL   (Australia)

Author keywords

Alzheimer's disease (AD); Cholesterol; Estrogen; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT; CHOLESTEROL; ESTROGEN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN CELL; BRAIN TISSUE; BREEDING METHOD; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGICAL DATA; ESTROGEN BLOOD LEVEL; ESTRUS CYCLE; FEMALE; GENDER; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; IMMUNOREACTIVITY; MALE; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RABBIT; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SEXUAL MATURITY; SPECIES DIFFERENTIATION; TISSUE DISTRIBUTION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0036449769     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04838.x     Document Type: Conference Paper

References (55)

1. Sparks, D.L. et al. 1990. Cortical senile plaques in coronary artery disease, aging, and Alzheimer's disease. Neurobiol. Aging 11: 601-607.
2. Sparks, D.L. et al. 1993. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J. Neuropathol. Exp. Neurol. 52: 135-142.
3. Sparks, D.L. 1997. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann. N.Y. Acad. Sci. 826: 128-146.
4. Sparks, D.L. 1997. Dietary cholesterol induces Alzheimer-like β-amyloid immunoreactivity in rabbit brain. Nutr. Metab. Cardiovasc. Dis. 7: 255-266.
5. Sparks, D.L. et al. 1994. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126: 88-94.
6. Sparks, D.L. et al. 2000. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: Preliminary observations. Ann. N.Y. Acad. Sci. 903: 335-344.
7. Sparks, D.L. 1996. Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol. Aging 17: 291-299.
8. Streit, W.J. & D.L. Sparks. 1997. Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J. Mol. Med. 75: 130-138.
9. Sparks, D.L. et al. 1995. Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci. Lett. 187: 142-144.
10. Sparks, D.L. 1999. Neuropathologic links between Alzheimer's disease and vascular disease. In Alzheimer's Disease and Related Disorders, pp. 153-163. Wiley. New York.
11. Bodovitz, S. & W.L. Klein. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271: 4436-4440.
12. Frears, E.R. et al. 1999. The role of cholesterol in the biosynthesis of β-amyloid. NeuroReport 10: 1699-1705.
13. Wolozin, B. et al. 1999. Decreased prevalence of Alzheimer's disease associated with HMG-CoA reductase inhibitors. Soc. Neurosci. 26: 16.
14. Durham, R.A. et al. 1998. Effect of age and diet on the expression of β-amyloid 1-40 and 1-42 in the brains of apolipoprotein-E-deficient mice. Neurobiol. Aging 19: S281.
15. Fishman, C.E. et al. 1999. High fat diet potentiates β-amyloid deposition in the APP V717F transgenic mouse model of Alzheimer's disease. Soc. Neurosci. 25: 1859.
16. Li, L. et al. 1999. Effects of an atherogenic diet on amyloidosis in transgenic mice overexpressing the C-terminal portion of β-amyloid precursor protein. Soc. Neurosci. 25: 1859.
17. Shie, F.S. et al. 1999. Effects of cholesterol feeding on histopathologic hallmarks of Alzheimer's disease in β-amyloid precursor protein (APP) transgenic mice. Soc. Neurosci. 25: 1859.
18. Koudinova, N.V. et al. 1996. Multiple inhibitory effects of Alzheimer's peptide Aβ1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett. 395: 204-206.
19. Runz, H. et al. 2002. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22: 1679-1689.
20. Wahrle, S. et al. 2002. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rick membrane microdomains. Neurobiol. Dis. 9:11-23.
21. Puglielli, L. et al. 2001. Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3: 905-912.
22. Howland, D.S. et al. 1998. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J. Biol. Chem. 273: 16576-16582.
23. Refolo, L.M. et al. 2001. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 5: 890-899.
24. Fassbender, K. et al. 2001. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. PNAS 98: 5371-5373.
25. Wolozin, B. et al. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443.
26. Jick, H. et al. 2000. Statins and the risk of dementia. Lancet 356: 1627-1631.
27. Yaffe, K. et al. 2002. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59: 378-384.
28. Tanzawa, K. et al. 1980. WHHL-rabbit: A low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS Lett. 18: 81-84.
29. Dietschy, J.M. et al. 1983. Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors. J. Lipid Res. 24. 469-480.
30. Tang, M.X. et al. 1996. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432.
31. Kawas, C. et al. 1997. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521.
32. Bachmann, G.A. 1999. Androgen cotherapy in menopause: Evolving benefits and challenges. Am. J. Obstet. Gynecol. 180: 308-311.
33. Mulnard, R.A. et al. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283: 1007-1015.
34. Henderson, V.W. et al. 2000. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 54: 295-301.
35. Asthana, S. et al. 2001. High-dose estradiol improves cognition for women with AD: Result of a randomized study. Neurology 57: 605-612.
36. Senanarong, V. et al. 2002. Endogenous estradiol in elderly individuals: Cognitive and noncognitive associations. Arch. Neurol. 59: 385-389.
37. Urabe, M. et al. 1996. Effects of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase, and lipids including apolipoprotein E in climacteric and elderly women. Endocr. J. 43: 737-742.
38. Genazzani, A.R. & M. Gambacciani. 1999. Hormone replacement therapy: The perspectives for the 21st century. Maturitas 32: 11-17.
39. Schiefeling, M. 1996. Prognostic features of menopausal and postmenopausal applicants for life insurance. J. Insur. Med. 28: 27-34.
40. Ohkura, T. et al. 1994. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause 2: 13-18.
41. Prelevic, G.M. & T. Beljic. 1994. The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 20: 37-44.
42. Watanabe, Y. 1980. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 36: 261-268.
43. Hoeg, J.M. et al. 1985. Impaired adrenal reserve in the Watanabe heritable hyperlipidemic rabbit: Implication for LDL-receptor function in steroidogenesis. Metabolism 34: 194-197.
44. Shiomi, M. et al. 2000. Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygous Watanabe heritable hyperlipidemic rabbits. Metabolism 49: 552-556.
45. Norido, F. et al. 1993. Hematologic and biochemical profiles of selectively bred WHHL rabbits. Lab. Anim. Sci. 43: 319-323.
46. Allain, P. et al. 1989. The distribution of elements in the tissues of Watanabe heritable hyperlipidemic rabbits. Biol. Trace Elem. Res. 19: 153-160.
47. Mortensen, A. & H. Frandsen. 1996. Reproductive performance and changes in blood lipids in breeding females and in growing Watanabe heritable hyperlipidemic and New Zealand white rabbits. Lab. Anim. 30: 252-259.
48. Esper, E. et al. 1993. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits: The effects of aging and gender on plasma lipids and lipoproteins. J. Lab. Clin. Med. 121: 97-102.
49. Robins, E.D. et al. 1994. Aberrant hypothalamic-pituitary-ovarian axis in the Watanabe heritable hyperlipidemic rabbit. J. Lipid Res. 35: 52-59.
50. Petanceska, S.S. et al. 2000. Ovariectomy and 17β-estradiol modulate the levels of Alzheimer's amyloid β peptides in brain. Exp. Gerontol. 35: 1317-1325.
51. Zheng, H. et al. 2002. Modulation of A(β) peptides by estrogen in mouse models. J. Neurochem. 80: 191-196.
52. Twist, S.J. et al. 2000. Brain oestradiol and testosterone levels in Alzheimer's disease. Neurosci. Lett. 286: 1-4.
53. Schonknecht, P. et al. 2001. Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci. Lett. 307: 122-124.
54. Manly, J.J. et al. 2000. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54: 833-837.
55. Cunningham, C.J. et al. 2001. Endogenous sex hormone levels in postmenopausal women with Alzheimer's disease. J. Clin. Endocrinol. Metab. 86: 1099-1103.